CNTA

MKT CAP:$6B

Centessa Pharmaceuticals plc

Market Cap

$6B

Healthcare·Biotechnology·🇬🇧 United Kingdom·NASDAQ

Healthcare·Biotechnology·🇬🇧·NASDAQ

Stock Price

$39.47+$15.78 (+66.61%)

Apr 22, 2026

Company Details

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that...

CEO

Mario Alberto Accardi

IPO Date

May 28, 2021

Website

www.centessa.com

Key Metrics TTM

Revenue

$15M

— YoY

Net Income

-$198M

EPS (Diluted)

-$1.46

Free Cash Flow

-$194M

Revenue / Share

$0.11

Gross Margin

100.0%

Operating Margin

-1384.6%

Net Margin

-1316.9%

FCF Margin

-1294.6%

P/S

392.7x

P/E

—

Earnings Reports

Q1 2026

May 13, 2026

PENDING

FY 2025

Mar 31, 2026

$0EPS -$1.46

Q4 2025

Mar 31, 2026

$0EPS -$0.47

Q3 2025

Nov 5, 2025

$0EPS -$0.41

Q2 2025

Aug 12, 2025

$0EPS -$0.38

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$53M
Q2 22	$0	$0	-$68M
Q3 22	$0	$0	-$49M
Q4 22	$0	$0	-$42M
Q1 23	$0	$0	-$49M
Q2 23	$0	$0	-$47M
Q3 23	$0	$0	-$40M
Q4 23	$7M	$7M	-$35M
Q1 24	$0	$0	-$36M
Q2 24	$0	$0	-$44M
Q3 24	$0	$0	-$46M
Q4 24	$0	$0	-$75M
Q1 25	$15M	$15M	-$31M
Q2 25	$0	$0	-$55M
Q3 25	$0	$0	-$54M
Q4 25	$0	$0	-$68M

Valuation

Quarter	P/S	P/E
Q1 22	—	—
Q2 22	—	—
Q3 22	—	—
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	103.5x	—
Q1 24	177.0x	—
Q2 24	149.3x	—
Q3 24	308.1x	—
Q4 24	—	—
Q1 25	127.5x	—
Q2 25	116.5x	—
Q3 25	217.4x	—
Q4 25	221.7x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$50M	-$50M
Q2 22	-$60M	-$60M
Q3 22	-$39M	-$39M
Q4 22	-$52M	-$52M
Q1 23	-$48M	-$48M
Q2 23	-$44M	-$44M
Q3 23	-$37M	-$37M
Q4 23	-$31M	-$31M
Q1 24	-$37M	-$37M
Q2 24	-$41M	-$41M
Q3 24	-$21M	-$21M
Q4 24	-$43M	-$43M
Q1 25	-$57M	-$57M
Q2 25	-$22M	-$23M
Q3 25	-$58M	-$59M
Q4 25	-$56M	-$56M

Capital Expenditures

Quarter	CapEx
Q1 22	$240.0K
Q2 22	$229.0K
Q3 22	$16.0K
Q4 22	$652.0K
Q1 23	$88.0K
Q2 23	$10.0K
Q3 23	$43.0K
Q4 23	$28.0K
Q1 24	$0
Q2 24	$1
Q3 24	$34.0K
Q4 24	$0
Q1 25	$3
Q2 25	$126.0K
Q3 25	$234.0K
Q4 25	$11.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+1671.0%
Q2 22	—	-71.1%
Q3 22	—	+18.7%
Q4 22	—	+8.6%
Q1 23	—	-8.2%
Q2 23	—	-31.3%
Q3 23	—	-18.0%
Q4 23	—	+1.0%
Q1 24	—	-26.2%
Q2 24	—	-6.5%
Q3 24	—	+15.4%
Q4 24	-100.0%	+77.4%
Q1 25	—	+26.8%
Q2 25	—	+24.3%
Q3 25	—	+15.9%
Q4 25	—	-8.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$6M	—
Q2 22	$6M	—
Q3 22	$7M	—
Q4 22	$7M	—
Q1 23	$7M	—
Q2 23	$7M	—
Q3 23	$8M	—
Q4 23	$7M	108.4%
Q1 24	$8M	—
Q2 24	$9M	—
Q3 24	$8M	—
Q4 24	$8M	—
Q1 25	$8M	52.6%
Q2 25	$8M	—
Q3 25	$7M	—
Q4 25	$8M	—

OpEx Breakdown

Quarter	R&D	G&A
Q1 22	$37M	$14M
Q2 22	$54M	$15M
Q3 22	$37M	$12M
Q4 22	$28M	$14M
Q1 23	$33M	$16M
Q2 23	$34M	$13M
Q3 23	$28M	$12M
Q4 23	$30M	$12M
Q1 24	$23M	$13M
Q2 24	$33M	$11M
Q3 24	$34M	$13M
Q4 24	$61M	$14M
Q1 25	$33M	$12M
Q2 25	$43M	$12M
Q3 25	$42M	$12M
Q4 25	$54M	$14M

Revenue Segments

Quarter	Reportable Segment
Q1 25	$15M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$544M	$0	$544M
Q2 22	$484M	$0	$484M
Q3 22	$445M	$0	$445M
Q4 22	$394M	$0	$394M
Q1 23	$260M	$86M	$346M
Q2 23	$145M	$158M	$304M
Q3 23	$171M	$110M	$281M
Q4 23	$128M	$129M	$257M
Q1 24	$118M	$112M	$230M
Q2 24	$127M	$167M	$295M
Q3 24	$395M	$123M	$518M
Q4 24	$383M	$99M	$482M
Q1 25	$105M	$179M	$285M
Q2 25	$44M	$206M	$251M
Q3 25	$51M	$195M	$246M
Q4 25	$61M	$233M	$295M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	91M	+0.7%	-15.0%
Q2 22	94M	+4.0%	+7.6%
Q3 22	94M	+0.2%	+48.5%
Q4 22	95M	+0.3%	+5.2%
Q1 23	95M	+0.4%	+4.9%
Q2 23	95M	+0.2%	+1.1%
Q3 23	97M	+1.6%	+2.5%
Q4 23	98M	+1.3%	+3.5%
Q1 24	100M	+2.0%	+5.2%
Q2 24	109M	+9.6%	+15.1%
Q3 24	116M	+6.2%	+20.3%
Q4 24	132M	+13.6%	+34.8%
Q1 25	133M	+0.7%	+33.2%
Q2 25	134M	+0.5%	+22.1%
Q3 25	134M	+0.4%	+15.4%
Q4 25	136M	+1.2%	+2.8%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	90
Q2 22	$0	90
Q3 22	$0	90
Q4 22	$0	83
Q1 23	$0	83
Q2 23	$0	83
Q3 23	$0	83
Q4 23	$90.2K	76
Q1 24	$0	76
Q2 24	$0	76
Q3 24	$0	76
Q4 24	$0	77
Q1 25	$194.8K	77
Q2 25	$0	77
Q3 25	$0	77
Q4 25	$0	175K

Revenue / Employee